XTL Biopharmaceuticals Ltd. XTLB

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
27/100
Developing

Ranked against 712 peers in Biotechnology

About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the … Full XTLB analysis →

Key risks

  • ROIC Below WACC or Peers ROIC at 0.3th percentile suggests inefficient capital deployment.
  • Elevated Debt Risk Debt serviceability is weak (score 0.36), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where XTLB ranks in Biotechnology

XTL Biopharmaceuticals Ltd. ranks #547 of 713 scored companies in Biotechnology by moat score — the top 77%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
543 Dermata Therapeutics, Inc. DRMA 27/100 Developing
544 Dermata Therapeutics, Inc. Warrant DRMAW 27/100 Developing
545 Oculis Holding AG OCS 27/100 Developing
546 Salarius Pharmaceuticals, Inc. SLRX 27/100 Developing
547 XTL Biopharmaceuticals Ltd. XTLB 27/100 Developing
548 Chimerix, Inc. CMRX 27/100 Developing
549 Larimar Therapeutics, Inc. LRMR 27/100 Developing
550 Unicycive Therapeutics, Inc. UNCY 27/100 Developing
551 ATAI Life Sciences N.V. ATAI 27/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How XTLB scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 67 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 12 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 25 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding XTLB's moat

What is XTL Biopharmaceuticals Ltd.'s moat score?

XTL Biopharmaceuticals Ltd. (XTLB) scores 27 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #547 of 713 scored companies in Biotechnology, the top 77%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (67/100) and its weakest is Capital Efficiency (12/100).

How does XTL Biopharmaceuticals Ltd. compare with other Biotechnology companies?

XTL Biopharmaceuticals Ltd. ranks #547 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Salarius Pharmaceuticals, Inc. (SLRX) at 27 just above it and Chimerix, Inc. (CMRX) at 27 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is XTL Biopharmaceuticals Ltd. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for XTL Biopharmaceuticals Ltd.?

The Corporate Default template measures 6 defenses, and XTLB scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (67), Capital Efficiency (12), Resilience (25), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000